Zolitrat

Zolitrat (Anastrozole) is an oral prescription medication used primarily for hormone receptor-positive breast cancer in postmenopausal women. It belongs to the aromatase inhibitor class, helping reduce estrogen levels. This product is manufactured by Rafarm Sa. in the EU.

Zolitrat is prescribed to treat hormone receptor-positive breast cancer in postmenopausal women. It works by lowering estrogen levels in the body, which can slow or stop the growth of certain types of breast cancer cells. This medication is often used after surgery or other initial treatments to reduce the risk of cancer recurrence. It may also be used in advanced breast cancer cases.

Zolitrat helps reduce estrogen production in the body, which can lead to a decrease in cancer cell growth. Many patients experience improved outcomes when using this medication as part of their treatment plan. Common effects may include hot flashes, joint pain, or fatigue, though individual experiences vary.

Zolitrat should be taken exactly as prescribed by a healthcare provider. It is important to discuss your full medical history with your doctor, especially if you have osteoporosis, liver disease, or a history of blood clots. Regular monitoring may be required to assess treatment progress and manage potential side effects.

Zolitrat may interact with other medications, including estrogen-containing drugs, tamoxifen, or strong CYP3A4 inhibitors. Alcohol and certain herbal supplements may also affect how Zolitrat works. Always inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions.